Author/Authors :
Amini, S Hepatitis and AIDS Department, Pasteur Institute of Iran, Department of Epidemiology and Biostatistics, School of Public Health, Institute of Public Health Research, University of Tehran, Tehran , Andalibi, S Hepatitis and AIDS Department, Pasteur Institute of Iran, Department of Epidemiology and Biostatistics, School of Public Health, Institute of Public Health Research, University of Tehran, Tehran , Mahmoodi, M Hepatitis and AIDS Department, Pasteur Institute of Iran, Department of Epidemiology and Biostatistics, School of Public Health, Institute of Public Health Research, University of Tehran, Tehran
Abstract :
Background: Following WHO recommendation, HBV vaccination
has been integrated into EPI program in Iran since 1996.
Objective: To evaluate the immunogenicity and protective effect of
HB vaccine (recombinant Heberbiovac ,Cuba ) in vaccinated children
and adults .
Methods: A total of 542 cases (340 children and 202 adults) were
vaccinated using a three-doses schedule of zero, one and six month.
Blood samples were collected before the last injection, one month,
one and two years after vaccination. Sera were tested for anti-HBs as
indicator of immune response.
Results: Seroconversion rates for anti-HBs after second dose was
97.9% in children and 87% in adults. After the third injection this
response increased to 100% and 93.7% in children and adults respectively.
The anti-HBs titer decreased after two years in both groups.
Conclusion: General vaccination with Heberbiovac vaccine in Iran
has been successful in provoking immune response and protection
against HBV infection. It seems that the persistence of the produced
immunity is higher in children than adults
Keywords :
Hepatitis B , antibody response , vaccination , immunization programs
